ESMO Congress 2026
Join Tempus at ESMO Congress 2026 as we showcase groundbreaking clinical research revealing meaningful insights in cancer biology, treatment response, and patient outcomes.
Experience live demos of our AI-powered technology and new product offerings designed to advance drug discovery and development.
Tempus Evening Reception
Join us for views of Madrid from the private club rooftop at Club Financiero Génova in Madrid to discover Tempus' groundbreaking work in precision medicine. Network with peers over food and light refreshments. RSVP is required.
Stop by our booth to discover how we are leveraging AI-enabled technologies to advance precision medicine.
Tempus Lens
Quickly find, access, and analyze multimodal de-identified data records and uncover critical insights to accelerate research and innovation. Leverage our Al assistant, Tempus One, to quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets in seconds. Explore unstructured clinical data and extract nuanced insights.
Foundation Models
Explore how our proprietary foundation models enable rapid AI application development and meaningful insights across the end-to-end drug development lifecycle, from discovery to clinical development and commercialization.
Clinicogenomic differences between early-onset (EO-PCa) and average-onset prostate cancer (AO-PCa): A retrospective cohort study
Presenting Author: Christos E. Kyriakopoulos, MD, University of Wisconsin School of Medicine and Public Health
Context-dependent prognostic impact of PTEN alterations (alt) in patients with metastatic androgen pathway modulation sensitive (mAPMS) prostate cancer
Presenting Author: Deepak Kilari, MD, Medical College of Wisconsin
De novo vs metachronous metastatic prostate pancer (mPC): A comprehensive clinicogenomic analysis
Presenting Author: Panagiotis J. Vlachostergios, MD, PhD, IASO Thessalias Hospital
Genomic characterization and prognostic impact of the TP53-Y220C mutation across solid tumors in real-world data
Presenting Author: Shivaani Kummar, MD, FACP, OHSU Knight Cancer Institute
Genomic landscape in early-onset breast cancer: A comprehensive analysis from the Tempus database
Presenting Author: Nerea Lopetegui-Lia, MD, The Ohio State University
Real-world implementation of large-panel ctDNA NGS testing in metastatic NSCLC and colorectal cancer: interim results of the multicenter LOLA Project
Presenting Author: Valeria C. Denninghoff, PhD, University of Granada
Novel immune archetypes stratify overall survival and refine the prognostic landscape in head and neck squamous cell carcinoma
Presenting Author: Zequn Sun, PhD, Northwestern University
A comprehensive AI-enabled pre-screening panel for non-small cell lung carcinoma (NSCLC) using computational pathology applied to H&E whole slide images (WSI)
Amy L. Cummings, MD, University of California, Los Angeles
Landscape of somatic alterations and real-world outcomes of ovarian cancer associated with ATM mutations.
Presenting Author: Gerneiva Parkinson, MD, Stanford University
Real-world impact of vascular endothelial growth factor (VEGF) on (chemo)immunotherapy (IO) response in non-small cell lung cancer (NSCLC)
Presenting Author: Amy L. Cummings, MD, University of California, Los Angeles
Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with advanced gynecologic malignancies
Presenting Author: Deandra Chetram, MD, Mayo Clinic - Rochester
Higher GCN2 Expression Is Associated with Favorable Clinical and Genomic Features in Advanced Prostate Cancer
Presenting Author: Bicky Thapa, MD, MS, FACP, Dana-Farber Cancer Institute
GCN2 RNA expression identifies a distinct immunologically cold and genomically favorable phenotype in advanced renal cell carcinoma
Presenting Author: Supriya Peshin, Norton Community Hospital, Ballad Health System
Schedule a meeting with us
We'll be in touch shortly.